Siegfried Holding AG successfully placed a subordinated public hybrid bond in the amount of CHF 145 million at a yearly coupon of 2.125%. The proceeds are used for capital structure management purposes and repayment of existing bank loans.
The instrument is perpetual with an initial option to redeem after five years. The hybrid bond is ranking pari-passu with the public hybrid bond of CHF 100 million, which was issued by Siegfried on 2 October 2015, as well as with the privately placed CHF 60 million hybrid convertible bond with RAG-Stiftung Beteiligungsgesellschaft mbH, which was issued by Siegfried on 29 September 2015. The bond will be applied for listing at SIX Swiss Exchange.
The bond offering attracted strong interest, particularly from Swiss investors, and was placed under the lead of UBS Investment Bank and Zürcher Kantonalbank.
Contact:
Michael Hüsler
Chief Financial Officer
michael.huesler@siegfried.ch
Tel. +41 62 746 11 35
Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen
Tel. +41 62 746 11 11
About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. Siegfried reported annual sales of CHF 481 million for 2015 and employs approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the SIX Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.
The instrument is perpetual with an initial option to redeem after five years. The hybrid bond is ranking pari-passu with the public hybrid bond of CHF 100 million, which was issued by Siegfried on 2 October 2015, as well as with the privately placed CHF 60 million hybrid convertible bond with RAG-Stiftung Beteiligungsgesellschaft mbH, which was issued by Siegfried on 29 September 2015. The bond will be applied for listing at SIX Swiss Exchange.
The bond offering attracted strong interest, particularly from Swiss investors, and was placed under the lead of UBS Investment Bank and Zürcher Kantonalbank.
Contact:
Michael Hüsler
Chief Financial Officer
michael.huesler@siegfried.ch
Tel. +41 62 746 11 35
Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen
Tel. +41 62 746 11 11
About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. Siegfried reported annual sales of CHF 481 million for 2015 and employs approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the SIX Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.
